After years of delays, NICE backs Celgene’s Revlimid in first-line MM

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2019 at 7:32 PM.

  1. #1 cafead, May 17, 2019 at 7:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,063
    Likes Received:
    3
    via After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with previously untreated multiple myeloma.

    article source
     
    Quote

Reply to Thread